hydroxychloroquine has been researched along with Rheumatic Diseases in 122 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Rheumatic Diseases: Disorders of connective tissue, especially the joints and related structures, characterized by inflammation, degeneration, or metabolic derangement.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Hydroxychloroquine (HCQ) is used in the treatment of inflammatory rheumatic diseases and is considered a safe drug." | 8.31 | Possible relationship between hydroxychloroquine and electrocardiographic and echocardiographic abnormalities in patients with inflammatory rheumatic diseases--a monocentric study. ( Costa, L; Macedo, F; Madureira, P; Martins Carvalho, M; Pinheiro, FO; Seabra Rato, M, 2023) |
| "To compare the incidence of COVID-19 in Spanish patients with autoimmune rheumatic diseases treated with and without hydroxychloroquine." | 8.02 | Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy. ( Corma, A; González-Moreno, P; González-Serna, A; Macho, M; Macías, J; Martínez, M; Morillo-Verdugo, R; Pérez-Venegas, JJ; Pineda, JA; Pinilla, A; Real, LM; Sánchez-García, E, 2021) |
| "Hydroxychloroquine (HCQ) is widely used to treat rheumatic diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS)." | 8.02 | Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study. ( Chan, KC; Li, LC; Lo, CH; Lo, TH; Su, CH; Tsai, CF; Wang, YH; Wei, JC, 2021) |
| " We examined medical records of patients with diabetes mellitus (DM) and concomitant rheumatic illness to measure changes in HbA(1c) after starting HCQ or methotrexate (MTX)." | 7.76 | Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. ( Bhatia, R; Garg, R; Gleeson, T; Lu, B; Massarotti, E; Rekedal, LR; Solomon, DH, 2010) |
| "A total of 40 infants born from mothers affected by rheumatic diseases and treated with hydroxychloroquine during pregnancy were enrolled in a prospective observational study." | 7.73 | Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. ( Biasini, C; Chirico, G; Faden, D; Frassi, M; Lojacono, A; Marchesi, A; Motta, M; Tincani, A; Zatti, S; Zinzini, E, 2005) |
| "Chronic use of chloroquine and hydroxychloroquine inthe treatment of rheumatic disease carries a small risk of sight-threatening pigmentary retinopathy." | 7.71 | Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. ( Buncic, RJ; Ito, S; Klinger, G; Koren, G; Laskin, C; Morad, Y; Spitzer, KA; Westall, CA, 2001) |
| "HCQ is a potential cause of sudden cardiac death in COVID-19 patients." | 6.72 | COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. ( Agarwal, V; Gupta, L; Raza, HA; Tariq, J, 2021) |
| "Hydroxychloroquine (HCQ) and chloroquine (CQ) are well absorbed (0." | 6.39 | Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ( Furst, DE, 1996) |
| "Hydroxychloroquine is an oral drug prescribed to pregnant women with rheumatic disease to reduce disease activity and prevent flares." | 5.51 | Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases. ( Balevic, SJ; Clowse, MEB; Cohen-Wolkowiez, M; Eudy, AM; Green, TP; Schanberg, LE, 2019) |
| "To check the ability of microperimetry to detect early retinal damage in patients with rheumatism taking hydroxychloroquine (HCQ), chloroquine (CQ), or both, and to describe the microperimetric alterations attributable to these drugs and their correlation with some clinical variables." | 5.17 | Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity. ( Beltrán-Catalán, E; Epifanio, I; Marco-Ventura, P; Martínez-Costa, L; Murcia-Bello, C; Verdejo-Gimeno, C; Victoria Ibañez, M, 2013) |
| "Hydroxychloroquine and quinacrine are frequently used to treat rheumatic diseases." | 5.01 | Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate? ( Samson, CM; Schwartzman, S, 2019) |
| "Despite advances in therapy for rheumatic diseases, hydroxychloroquine remains almost universally recommended for the treatment of systemic lupus erythematosus (SLE), and is often used in the management of other rheumatic diseases such as rheumatoid arthritis (RA)." | 4.98 | Hydroxychloroquine retinopathy - implications of research advances for rheumatology care. ( Choi, HK; Jorge, A; Melles, RB; Ung, C; Young, LH, 2018) |
| "The antimalarial drugs chloroquine (CQ) and hydroxychloroquine (HCQ) have been used for decades to treat rheumatic diseases." | 4.87 | Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature. ( Koren, G; Osadchy, A; Ratnapalan, T, 2011) |
| "Hydroxychloroquine is an effective treatment for rheumatic diseases; however, retinal damage is a possible side effect." | 4.31 | Cone Density Distribution and Related Factors in Patients Receiving Hydroxychloroquine Treatment. ( Huang, H; Liu, H; Liu, X; Mo, S; Tang, J; Zhu, Z, 2023) |
| "Hydroxychloroquine (HCQ) is used in the treatment of inflammatory rheumatic diseases and is considered a safe drug." | 4.31 | Possible relationship between hydroxychloroquine and electrocardiographic and echocardiographic abnormalities in patients with inflammatory rheumatic diseases--a monocentric study. ( Costa, L; Macedo, F; Madureira, P; Martins Carvalho, M; Pinheiro, FO; Seabra Rato, M, 2023) |
| "Hydroxychloroquine (HCQ) is widely used to treat rheumatic diseases including rheumatoid arthritis (RA), systemic lupus erythematosus (SLE) and Sjögren's syndrome (SS)." | 4.02 | Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study. ( Chan, KC; Li, LC; Lo, CH; Lo, TH; Su, CH; Tsai, CF; Wang, YH; Wei, JC, 2021) |
| "To ascertain if the use of hydroxychloroquine(HCQ)/cloroquine(CLQ) and other conventional DMARDs (cDMARDs) and rheumatic diseases per se may be associated with COVID-19-related risk of hospitalization and mortality." | 4.02 | Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy. ( Atzeni, F; Baracco, S; Belleudi, V; Crisafulli, S; Ferroni, E; Gini, R; Giorgi Rossi, P; Kirchmayer, U; Kurotschka, PK; Leoni, O; Ludergnani, M; Mancuso, P; Massari, M; Salvarani, C; Spila Alegiani, S; Trifirò, G, 2021) |
| "To compare the incidence of COVID-19 in Spanish patients with autoimmune rheumatic diseases treated with and without hydroxychloroquine." | 4.02 | Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy. ( Corma, A; González-Moreno, P; González-Serna, A; Macho, M; Macías, J; Martínez, M; Morillo-Verdugo, R; Pérez-Venegas, JJ; Pineda, JA; Pinilla, A; Real, LM; Sánchez-García, E, 2021) |
| "Chloroquine and hydroxychloroquine at lower doses, as used in rheumatic diseases, prove to be relatively safe." | 4.02 | Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective. ( Grygiel-Górniak, B; Majewska, KA; Majewski, D; Naskręcka, M, 2021) |
| " We examined medical records of patients with diabetes mellitus (DM) and concomitant rheumatic illness to measure changes in HbA(1c) after starting HCQ or methotrexate (MTX)." | 3.76 | Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases. ( Bhatia, R; Garg, R; Gleeson, T; Lu, B; Massarotti, E; Rekedal, LR; Solomon, DH, 2010) |
| "A total of 40 infants born from mothers affected by rheumatic diseases and treated with hydroxychloroquine during pregnancy were enrolled in a prospective observational study." | 3.73 | Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation. ( Biasini, C; Chirico, G; Faden, D; Frassi, M; Lojacono, A; Marchesi, A; Motta, M; Tincani, A; Zatti, S; Zinzini, E, 2005) |
| " It was diagnosed to be a case of palindromic rheumatism clinically and treated with hydroxychloroquine." | 3.71 | Palindromic rheumatism. ( Singhal, S; Zahid, M, 2002) |
| "Chronic use of chloroquine and hydroxychloroquine inthe treatment of rheumatic disease carries a small risk of sight-threatening pigmentary retinopathy." | 3.71 | Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases. ( Buncic, RJ; Ito, S; Klinger, G; Koren, G; Laskin, C; Morad, Y; Spitzer, KA; Westall, CA, 2001) |
| "Specific information concerning the use of nonsteroidal anti-inflammatory agents, salicylates, analgesics, remittive drugs, and other adjunctive treatments used for rheumatic diseases are addressed." | 3.67 | The use of drugs in rheumatic diseases. ( Gall, EP, 1984) |
| "HCQ is a potential cause of sudden cardiac death in COVID-19 patients." | 2.72 | COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases. ( Agarwal, V; Gupta, L; Raza, HA; Tariq, J, 2021) |
| "Hydroxychloroquine was not beneficial at any disease stage, one RCT with anakinra was negative, one RCT with baricitinib+remdesivir was positive, and individual trials on some other compounds provided interesting, although preliminary, results." | 2.72 | Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider. ( Alunno, A; De Marco, G; Emmel, J; Machado, PM; Mariette, X; Mason, L; McGonagle, DG; Najm, A, 2021) |
| "Pre-existing maculopathy, renal insufficiency (glomerular filtration rate, GFR <60 ml/min), tamoxifen comedication, a daily dose of >5 mg/kg HCQ or treatment with chloroquine (CQ) show an increased risk for AM-induced retinopathy." | 2.66 | [Safety management of the treatment with antimalarial drugs in rheumatology. Interdisciplinary recommendations based on a systematic literature search]. ( Detert, J; Fiehn, C; Hadjiski, D; Krüger, K; Ness, T; Specker, C; Weseloh, C, 2020) |
| "Antimalarial drugs including chloroquine, its less toxic quinolone-derivative hydroxychloroquine (HCQ), and quinacrine have become cornerstones in the treatment of autoimmune diseases including systemic lupus, rheumatoid arthritis, sarcoidosis, and Sjogren syndrome; cutaneous disorders, antiphospholipid syndrome, and have recently been employed at higher dioses in oncology." | 2.58 | Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update. ( Abdulaziz, N; McCune, WJ; Shah, AR, 2018) |
| "HCQ is widely used for the treatment of rheumatic diseases, particularly lupus and RA." | 2.53 | Hydroxychloroquine-related retinal toxicity. ( Denniston, AK; Ding, HJ; Gordon, C; Rao, VK, 2016) |
| "Hydroxychloroquine (HCQ) and chloroquine (CQ) are well absorbed (0." | 2.39 | Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases. ( Furst, DE, 1996) |
| " Taken together, these data suggest that more effective dosage regimens will be possible when therapeutic concentration ranges are properly established." | 2.38 | Antimalarials in rheumatic diseases. ( Cutler, D; Day, R; Tett, S, 1990) |
| "As sarcoidosis is a mimicking disease, a good differential diagnosis should be made to avoid misdiagnosis and in order not to be late in diagnosis and treatment." | 1.72 | Perspective of sarcoidosis in terms of rheumatology: a single-center rheumatology clinic experience. ( Duruöz, MT; Esen, İ; Gezer, HH; Karabulut, Y; Öz, N, 2022) |
| "Hydroxychloroquine (HCQ) has been promoted as a potential treatment of coronavirus disease 2019 (COVID-19), but there are safety concerns." | 1.56 | Effects of hydroxychloroquine treatment on QT interval. ( Adabag, S; Bart, B; Hooks, M; Vardeny, O; Westanmo, A, 2020) |
| "Rheumatic diseases were IA (60%) and CTD (40%)." | 1.56 | Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study. ( Alvaro-Gracia, JM; Blanco, R; Carmona, L; Castrejón, I; Fernández Fernández, D; Fernandez-Nebro, A; Galindo, M; Gonzalez-Gay, MA; Lledó, A; Manrique-Arija, S; Martinez-Lopez, D; Mena Vázquez, N; Mera-Varela, A; Pablos, JL; Retuerto, M, 2020) |
| "Hydroxychloroquine is an oral drug prescribed to pregnant women with rheumatic disease to reduce disease activity and prevent flares." | 1.51 | Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases. ( Balevic, SJ; Clowse, MEB; Cohen-Wolkowiez, M; Eudy, AM; Green, TP; Schanberg, LE, 2019) |
| " The relationships between the RNFL thicknesses and the duration or cumulative dosage of HCQ use were analyzed." | 1.48 | Peripapillary Retinal Nerve Fiber Layer Thicknesses Did Not Change in Long-term Hydroxychloroquine Users. ( Cha, HS; Eo, DR; Ham, DI; Han, JC; Kang, SW; Kee, C; Kim, SJ; Koh, EM; Lee, EJ; Lee, J; Lee, MG, 2018) |
| "To study the adherence of rheumatologists to the hydroxychloroquine (HCQ) dosing guidelines established by the American Academy of Ophthalmology in 2011 and 2016." | 1.46 | Adherence to Hydroxychloroquine Dosing Guidelines by Rheumatologists: An Electronic Medical Record-Based Study in an Integrated Health Care System. ( Braslow, RA; Macsai, MS; Shiloach, M, 2017) |
| " However, its long-term use is known to be associated with visual changes due to retinal damage." | 1.42 | Early effect of hydroxychloroquine therapy: relationship between cumulative dose and retinal thickness. ( Agarwal, P; Agarwal, R; Chyn, GS; Dasgupta, E; Livingstone, BI; Ramamurthy, S; Wong, YH, 2015) |
| "Hydroxychloroquine (HCQ) is an antimalarial agent with immunomodulatory effects." | 1.33 | Desensitization to hydroxychloroquine--experience of 4 patients. ( Breuer, GS; Mates, M; Navon, P; Nesher, G; Zevin, S, 2006) |
| " Depression of extra-oculogram is an early sign of excessive dosage and can be used to measure potential toxicity during therapy with 4-aminoquinolines." | 1.27 | Pharmacologic actions of 4-aminoquinoline compounds. ( Mackenzie, AH, 1983) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 16 (13.11) | 18.7374 |
| 1990's | 15 (12.30) | 18.2507 |
| 2000's | 11 (9.02) | 29.6817 |
| 2010's | 33 (27.05) | 24.3611 |
| 2020's | 47 (38.52) | 2.80 |
| Authors | Studies |
|---|---|
| Haase, I | 1 |
| Fischer-Betz, R | 2 |
| Pileggi, GS | 2 |
| Ferreira, GA | 2 |
| Reis, APMG | 1 |
| Reis-Neto, ET | 2 |
| Abreu, MM | 2 |
| Albuquerque, CP | 2 |
| Araújo, NC | 2 |
| Bacchiega, AB | 2 |
| Bianchi, DV | 2 |
| Bica, B | 2 |
| Bonfa, ED | 1 |
| Borba, EF | 2 |
| Brito, DCSE | 1 |
| Duarte, ÂLBP | 1 |
| Santo, RCE | 1 |
| Fernandes, PR | 2 |
| Guimarães, MP | 2 |
| Gomes, KWP | 1 |
| Kakehasi, AM | 2 |
| Klumb, EM | 2 |
| Lanna, CCD | 1 |
| Marques, CDL | 2 |
| Monticielo, OA | 2 |
| Mota, LMH | 2 |
| Munhoz, GA | 2 |
| Paiva, ES | 2 |
| Pereira, HLA | 2 |
| Provenza, JR | 2 |
| Ribeiro, SLE | 2 |
| Junior, LFR | 1 |
| Sampaio, CSJC | 1 |
| Sampaio, VS | 1 |
| Sato, EI | 2 |
| Skare, T | 2 |
| de Souza, VA | 2 |
| Valim, V | 2 |
| Lacerda, MVG | 2 |
| Xavier, RM | 2 |
| Pinheiro, MM | 2 |
| Oztas, M | 1 |
| Bektas, M | 1 |
| Karacan, I | 1 |
| Aliyeva, N | 1 |
| Dag, A | 1 |
| Aghamuradov, S | 1 |
| Cevirgen, SB | 1 |
| Sari, S | 1 |
| Bolayirli, M | 1 |
| Can, G | 1 |
| Hatemi, G | 1 |
| Seyahi, E | 1 |
| Ozdogan, H | 1 |
| Gul, A | 1 |
| Ugurlu, S | 1 |
| Karabulut, Y | 1 |
| Öz, N | 1 |
| Gezer, HH | 1 |
| Esen, İ | 1 |
| Duruöz, MT | 1 |
| Gentry, CA | 1 |
| Thind, SK | 1 |
| Williams, RJ | 1 |
| Hendrickson, SC | 1 |
| Kurdgelashvili, G | 1 |
| Humphrey, MB | 1 |
| Zheng, YQ | 1 |
| Li, HJ | 1 |
| Chen, L | 1 |
| Lin, SP | 1 |
| Pinheiro, FO | 1 |
| Martins Carvalho, M | 1 |
| Madureira, P | 1 |
| Seabra Rato, M | 1 |
| Macedo, F | 1 |
| Costa, L | 1 |
| Tang, J | 1 |
| Liu, H | 1 |
| Mo, S | 1 |
| Zhu, Z | 1 |
| Huang, H | 1 |
| Liu, X | 1 |
| Adamptey, B | 1 |
| Rudnisky, CJ | 1 |
| MacDonald, IM | 1 |
| Jayaprakash, A | 1 |
| K, S | 1 |
| Fiehn, C | 1 |
| Ness, T | 1 |
| Weseloh, C | 1 |
| Specker, C | 1 |
| Hadjiski, D | 1 |
| Detert, J | 1 |
| Krüger, K | 1 |
| Yazdany, J | 1 |
| Kim, AHJ | 1 |
| Marotto, D | 1 |
| Sarzi-Puttini, P | 1 |
| Xie, W | 1 |
| Wang, Y | 1 |
| Zhang, Z | 1 |
| Licciardi, F | 1 |
| Giani, T | 1 |
| Baldini, L | 1 |
| Favalli, EG | 1 |
| Caporali, R | 1 |
| Cimaz, R | 1 |
| Monti, S | 2 |
| Montecucco, C | 3 |
| Parisi, S | 1 |
| Ditto, MC | 1 |
| Finucci, A | 1 |
| Fusaro, E | 1 |
| Mikuls, TR | 1 |
| Johnson, SR | 1 |
| Fraenkel, L | 1 |
| Arasaratnam, RJ | 1 |
| Baden, LR | 1 |
| Bermas, BL | 2 |
| Chatham, W | 1 |
| Cohen, S | 1 |
| Costenbader, K | 1 |
| Gravallese, EM | 1 |
| Kalil, AC | 1 |
| Weinblatt, ME | 1 |
| Winthrop, K | 1 |
| Mudano, AS | 1 |
| Turner, A | 1 |
| Saag, KG | 1 |
| Graef, ER | 1 |
| Liew, JW | 1 |
| Kim, AH | 1 |
| Sparks, JA | 1 |
| Erre, GL | 1 |
| Ferraccioli, ES | 2 |
| Piga, M | 1 |
| Mangoni, A | 1 |
| Passiu, G | 1 |
| Gremese, E | 2 |
| Ferraccioli, G | 2 |
| Kucharz, EJ | 1 |
| Balevic, SJ | 2 |
| Hornik, CP | 1 |
| Green, TP | 2 |
| Clowse, MEB | 2 |
| Gonzalez, D | 1 |
| Maharaj, AR | 1 |
| Schanberg, LE | 2 |
| Eudy, AM | 2 |
| Swamy, GK | 1 |
| Hughes, BL | 1 |
| Cohen-Wolkowiez, M | 2 |
| Joob, B | 1 |
| Wiwanitkit, V | 1 |
| Hodkinson, B | 1 |
| Singh, P | 1 |
| Gcelu, A | 1 |
| Bautista-Molano, W | 1 |
| Pons-Estel, G | 1 |
| Alpízar-Rodríguez, D | 1 |
| Bozzalla Cassione, E | 1 |
| Zanframundo, G | 1 |
| Biglia, A | 1 |
| Codullo, V | 1 |
| Cavagna, L | 2 |
| Sanchez-Piedra, C | 1 |
| Diaz-Torne, C | 1 |
| Manero, J | 1 |
| Pego-Reigosa, JM | 1 |
| Rúa-Figueroa, Í | 1 |
| Gonzalez-Gay, MA | 2 |
| Gomez-Reino, J | 1 |
| Alvaro-Gracia, JM | 2 |
| Gamboa-Alonso, CM | 1 |
| Figueroa-Parra, G | 1 |
| Galarza-Delgado, DA | 2 |
| Pineda-Sic, RA | 1 |
| Serna-Peña, G | 1 |
| Castillo-Torres, SA | 1 |
| Flores-Alvarado, DE | 1 |
| Esquivel-Valerio, JA | 1 |
| Hernández-Galarza, IJ | 1 |
| Nuño, L | 1 |
| Novella Navarro, M | 1 |
| Bonilla, G | 1 |
| Franco-Gómez, K | 1 |
| Aguado, P | 1 |
| Peiteado, D | 1 |
| Monjo, I | 1 |
| Tornero, C | 1 |
| Villalba, A | 1 |
| Miranda-Carus, ME | 1 |
| De Miguel, E | 1 |
| Bogas, P | 1 |
| Castilla-Plaza, A | 1 |
| Bernad-Pineda, M | 1 |
| García-Lorenzo, E | 1 |
| Rodríguez-Araya, T | 1 |
| Balsa, A | 1 |
| Hooks, M | 1 |
| Bart, B | 1 |
| Vardeny, O | 1 |
| Westanmo, A | 1 |
| Adabag, S | 1 |
| Akintayo, RO | 1 |
| Akpabio, A | 1 |
| Kalla, A | 1 |
| Dey, D | 1 |
| Migowa, A | 1 |
| Olaosebikan, H | 1 |
| Bahiri, R | 1 |
| El Miedany, Y | 1 |
| Hadef, D | 1 |
| Hamdi, W | 1 |
| Oyoo, O | 1 |
| Slimani, S | 1 |
| Yerima, A | 1 |
| Taha, Y | 1 |
| Adebajo, A | 1 |
| Adelowo, O | 1 |
| Tikly, M | 1 |
| Ghozlani, I | 1 |
| Abdelghani, KB | 1 |
| Fouad, NA | 1 |
| Mosad, D | 1 |
| El Mikkawy, D | 1 |
| Abu-Zaid, MH | 1 |
| Abdel-Magied, RA | 1 |
| Alivernini, S | 1 |
| Tolusso, B | 1 |
| Gheita, TA | 1 |
| Salem, MN | 1 |
| Eesa, NN | 1 |
| Khalil, NM | 1 |
| Gamal, NM | 1 |
| Noor, RA | 1 |
| Moshrif, AH | 1 |
| Shereef, RE | 1 |
| Ismail, F | 1 |
| Noshy, N | 1 |
| Fawzy, RM | 1 |
| Elshebini, E | 1 |
| Khalifa, I | 1 |
| Saadany, HE | 1 |
| Tharwat, S | 1 |
| El-Najjar, A | 1 |
| Fattah, YA | 1 |
| Sallam, R | 1 |
| El-Bahnasawy, AS | 1 |
| Gharbia, O | 1 |
| Hassan, E | 1 |
| ElShanawany, A | 1 |
| Mohamed, EF | 1 |
| Senara, S | 1 |
| Ismail, M | 1 |
| Nasef, SI | 1 |
| Abdalla, AM | 1 |
| Elessawi, D | 1 |
| Fawzy, SM | 1 |
| Alfadl, EA | 1 |
| Khalifa, A | 1 |
| Abaza, NM | 1 |
| Santos, CS | 1 |
| Morales, CM | 1 |
| Álvarez, ED | 1 |
| Castro, CÁ | 1 |
| Robles, AL | 1 |
| Sandoval, TP | 1 |
| Lin, C | 1 |
| Wang, Z | 1 |
| Li, J | 1 |
| Xia, X | 1 |
| Liu, Y | 1 |
| Wang, Q | 1 |
| Pablos, JL | 1 |
| Galindo, M | 1 |
| Carmona, L | 1 |
| Lledó, A | 1 |
| Retuerto, M | 1 |
| Blanco, R | 1 |
| Martinez-Lopez, D | 1 |
| Castrejón, I | 1 |
| Fernández Fernández, D | 1 |
| Mera-Varela, A | 1 |
| Manrique-Arija, S | 1 |
| Mena Vázquez, N | 1 |
| Fernandez-Nebro, A | 1 |
| Mathian, A | 1 |
| Amoura, Z | 1 |
| Murray, K | 1 |
| Quinn, S | 1 |
| Turk, M | 1 |
| O'Rourke, A | 1 |
| Molloy, E | 1 |
| O'Neill, L | 1 |
| Mongey, AB | 1 |
| Fearon, U | 1 |
| Veale, DJ | 1 |
| Raza, HA | 1 |
| Tariq, J | 1 |
| Agarwal, V | 1 |
| Gupta, L | 1 |
| Duffy, E | 1 |
| Arroll, N | 1 |
| Beasley, R | 1 |
| Hills, T | 1 |
| Alunno, A | 1 |
| Najm, A | 1 |
| Mariette, X | 1 |
| De Marco, G | 1 |
| Emmel, J | 1 |
| Mason, L | 1 |
| McGonagle, DG | 1 |
| Machado, PM | 1 |
| Majewski, D | 1 |
| Majewska, KA | 1 |
| Naskręcka, M | 1 |
| Grygiel-Górniak, B | 1 |
| Macías, J | 1 |
| González-Moreno, P | 1 |
| Sánchez-García, E | 1 |
| Morillo-Verdugo, R | 1 |
| Pérez-Venegas, JJ | 1 |
| Pinilla, A | 1 |
| Macho, M | 1 |
| Martínez, M | 1 |
| González-Serna, A | 1 |
| Corma, A | 1 |
| Real, LM | 1 |
| Pineda, JA | 1 |
| Spila Alegiani, S | 1 |
| Crisafulli, S | 1 |
| Giorgi Rossi, P | 1 |
| Mancuso, P | 1 |
| Salvarani, C | 1 |
| Atzeni, F | 1 |
| Gini, R | 1 |
| Kirchmayer, U | 1 |
| Belleudi, V | 1 |
| Kurotschka, PK | 1 |
| Leoni, O | 1 |
| Ludergnani, M | 1 |
| Ferroni, E | 1 |
| Baracco, S | 1 |
| Massari, M | 1 |
| Trifirò, G | 1 |
| Lo, CH | 1 |
| Wei, JC | 1 |
| Wang, YH | 1 |
| Tsai, CF | 1 |
| Chan, KC | 1 |
| Li, LC | 1 |
| Lo, TH | 1 |
| Su, CH | 1 |
| Gomides Reis, APM | 1 |
| Bonfa, E | 1 |
| Egypto Brito, DCS | 1 |
| Calderaro, DC | 1 |
| Pinto Duarte, ÂLB | 1 |
| Espírito Santo, RC | 1 |
| Poti Gomes, KW | 1 |
| Faustino Ilana, GG | 1 |
| Guedes de Melo, AK | 1 |
| Rocha, LF | 1 |
| Martí-Carvajal, A | 1 |
| Ramon-Pardo, P | 1 |
| Javelle, E | 1 |
| Simon, F | 1 |
| Aldighieri, S | 1 |
| Horvath, H | 1 |
| Rodriguez-Abreu, J | 1 |
| Reveiz, L | 1 |
| Piscianz, E | 1 |
| Cuzzoni, E | 1 |
| Sharma, R | 1 |
| Tesser, A | 1 |
| Sapra, P | 1 |
| Tommasini, A | 1 |
| Ahn, SJ | 1 |
| Joung, J | 1 |
| Lim, HW | 1 |
| Lee, BR | 1 |
| Abdulaziz, N | 1 |
| Shah, AR | 1 |
| McCune, WJ | 1 |
| Allahdina, AM | 1 |
| Stetson, PF | 1 |
| Vitale, S | 1 |
| Wong, WT | 1 |
| Chew, EY | 1 |
| Ferris, FL | 1 |
| Sieving, PA | 1 |
| Cukras, C | 1 |
| Ruberto, G | 1 |
| Bruttini, C | 1 |
| Tinelli, C | 1 |
| Bianchi, A | 1 |
| Milano, G | 1 |
| Barsalou, J | 1 |
| Costedoat-Chalumeau, N | 1 |
| Berhanu, A | 1 |
| Fors-Nieves, C | 1 |
| Shah, U | 1 |
| Brown, P | 1 |
| Laskin, CA | 1 |
| Morel, N | 1 |
| Levesque, K | 1 |
| Buyon, JP | 2 |
| Silverman, ED | 1 |
| Izmirly, PM | 1 |
| Jorge, A | 1 |
| Ung, C | 1 |
| Young, LH | 1 |
| Melles, RB | 3 |
| Choi, HK | 1 |
| Goker, YS | 1 |
| Ucgul Atılgan, C | 1 |
| Tekin, K | 1 |
| Kızıltoprak, H | 1 |
| Yetkin, E | 1 |
| Yesil Karahan, N | 1 |
| Koc, M | 1 |
| Kosekahya, P | 1 |
| Lee, EJ | 1 |
| Kim, SJ | 3 |
| Han, JC | 1 |
| Eo, DR | 2 |
| Lee, MG | 3 |
| Ham, DI | 3 |
| Kang, SW | 3 |
| Kee, C | 2 |
| Lee, J | 3 |
| Cha, HS | 3 |
| Koh, EM | 2 |
| Schwartzman, S | 1 |
| Samson, CM | 1 |
| Martínez-Costa, L | 1 |
| Victoria Ibañez, M | 1 |
| Murcia-Bello, C | 1 |
| Epifanio, I | 1 |
| Verdejo-Gimeno, C | 1 |
| Beltrán-Catalán, E | 1 |
| Marco-Ventura, P | 1 |
| Agarwal, P | 1 |
| Wong, YH | 1 |
| Dasgupta, E | 1 |
| Agarwal, R | 1 |
| Livingstone, BI | 1 |
| Ramamurthy, S | 1 |
| Chyn, GS | 1 |
| Marmor, MF | 3 |
| Johnston, JL | 1 |
| Darvill, P | 1 |
| Thomson, GT | 1 |
| Lee, DH | 1 |
| Joe, SG | 1 |
| Lee, JY | 1 |
| Kim, JG | 1 |
| Lee, CK | 1 |
| Yoo, B | 1 |
| Koo, BS | 1 |
| Kim, JT | 1 |
| Yoon, YH | 1 |
| Ding, HJ | 1 |
| Denniston, AK | 1 |
| Rao, VK | 1 |
| Gordon, C | 1 |
| Rosenbaum, JT | 1 |
| Mount, GR | 1 |
| Youssef, J | 1 |
| Lin, P | 1 |
| Koh, E | 1 |
| Braslow, RA | 1 |
| Shiloach, M | 1 |
| Macsai, MS | 1 |
| Hu, C | 1 |
| Lu, L | 1 |
| Wan, JP | 1 |
| Wen, C | 1 |
| Goucha, S | 1 |
| Khaled, A | 1 |
| Kharfi, M | 1 |
| Fazaa, B | 1 |
| Zermani, R | 1 |
| Ben Jilani, S | 1 |
| Kamoun, MR | 1 |
| Nebbioso, M | 1 |
| Livani, ML | 1 |
| Steigerwalt, RD | 1 |
| Panetta, V | 1 |
| Rispoli, E | 1 |
| Rekedal, LR | 1 |
| Massarotti, E | 1 |
| Garg, R | 1 |
| Bhatia, R | 1 |
| Gleeson, T | 1 |
| Lu, B | 1 |
| Solomon, DH | 1 |
| Katz, SJ | 1 |
| Russell, AS | 3 |
| Heravian, J | 1 |
| Saghafi, M | 1 |
| Shoeibi, N | 1 |
| Hassanzadeh, S | 1 |
| Shakeri, MT | 1 |
| Sharepoor, M | 1 |
| Osadchy, A | 1 |
| Ratnapalan, T | 1 |
| Koren, G | 2 |
| Missner, S | 1 |
| Kellner, U | 1 |
| Kishimoto, M | 1 |
| Deshpande, GA | 1 |
| Yokogawa, N | 1 |
| Okada, M | 1 |
| Miller, AV | 1 |
| Ranatunga, SK | 1 |
| Singhal, S | 1 |
| Zahid, M | 1 |
| Schiemann, U | 1 |
| Kellner, H | 1 |
| Klaukka, T | 1 |
| Kaarela, K | 1 |
| NIEWEG, HO | 1 |
| BOUMA, HG | 1 |
| DEVRIES, K | 1 |
| JANSZ, A | 1 |
| KERUZORE, A | 1 |
| COSTE, F | 1 |
| DELBARRE, F | 1 |
| Tzekov, RT | 1 |
| Serrato, A | 1 |
| Motta, M | 1 |
| Tincani, A | 1 |
| Faden, D | 1 |
| Zinzini, E | 1 |
| Lojacono, A | 1 |
| Marchesi, A | 1 |
| Frassi, M | 1 |
| Biasini, C | 1 |
| Zatti, S | 1 |
| Chirico, G | 1 |
| Casado, E | 1 |
| Gratacós, J | 1 |
| Tolosa, C | 1 |
| Martínez, JM | 1 |
| Ojanguren, I | 1 |
| Ariza, A | 1 |
| Real, J | 1 |
| Sanjuán, A | 1 |
| Larrosa, M | 1 |
| Mates, M | 1 |
| Zevin, S | 1 |
| Breuer, GS | 1 |
| Navon, P | 1 |
| Nesher, G | 1 |
| Muslimani, AA | 1 |
| Spiro, TP | 1 |
| Chaudhry, AA | 1 |
| Daw, HA | 1 |
| Sontheimer, RD | 1 |
| Gall, EP | 1 |
| Mackenzie, AH | 1 |
| Waytz, PH | 1 |
| Pattee, JJ | 1 |
| Middleton, GD | 1 |
| McFarlin, JE | 1 |
| Lipsky, PE | 1 |
| Cutler, DJ | 1 |
| Schaller, JG | 1 |
| Anderson, RJ | 1 |
| Senécal, JL | 1 |
| Chartier, S | 1 |
| Rothfield, N | 1 |
| Fox, R | 1 |
| Furst, DE | 1 |
| Silman, A | 1 |
| Shipley, M | 1 |
| Rynes, RI | 1 |
| Schiavon, F | 1 |
| Punzi, L | 1 |
| Todesco, S | 1 |
| Clarke, AK | 1 |
| Aviña-Zubieta, JA | 1 |
| Galindo-Rodriguez, G | 1 |
| Newman, S | 1 |
| Suarez-Almazor, ME | 1 |
| Hollister, JR | 1 |
| Klinger, G | 1 |
| Morad, Y | 1 |
| Westall, CA | 1 |
| Laskin, C | 1 |
| Spitzer, KA | 1 |
| Ito, S | 1 |
| Buncic, RJ | 1 |
| Meyer, W | 1 |
| Weyerbrock, W | 1 |
| Evens, RP | 1 |
| Kolodny, AL | 1 |
| Klipper, AR | 1 |
| Reardon, EV | 1 |
| Clough, JD | 1 |
| Tett, S | 1 |
| Cutler, D | 1 |
| Day, R | 1 |
| Wright, V | 1 |
| Dixon, JS | 1 |
| Bird, HA | 1 |
| McWhorter, JE | 1 |
| Dugowson, CE | 1 |
| Gilliland, BC | 1 |
| Maksymowych, W | 1 |
| Morris, RG | 1 |
| Henkind, P | 1 |
| Gold, DH | 1 |
| Vlcek, F | 1 |
| Jones, BR | 1 |
| Voop, HV | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Evaluation of a New Score Incorporating Endothelial Dysfunction for the Assessment of Coronary Heart Disease Risk in Patients With Rheumatoid Arthritis: a 3-year Prospective Study.[NCT02341066] | 3,000 participants (Anticipated) | Observational | 2015-07-31 | Recruiting | |||
| A Multi Center Randomized Open Label Trial on the Safety and Efficacy of Chloroquine for the Treatment of Hospitalized Adults With Laboratory Confirmed SARS-CoV-2 Infection in Vietnam[NCT04328493] | Phase 2 | 10 participants (Actual) | Interventional | 2020-04-07 | Completed | ||
| Hydroxychloroquine in Unexplained Recurrent Pregnancy Loss ,Double Blinded Randomized Controlled Trial .[NCT05237843] | Phase 1 | 70 participants (Anticipated) | Interventional | 2022-03-01 | Not yet recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
29 reviews available for hydroxychloroquine and Rheumatic Diseases
| Article | Year |
|---|---|
[State of the art: fertility and pregnancy in rheumatic diseases].
Topics: Female; Fertility; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pregnancy; Pregnancy C | 2021 |
[Safety management of the treatment with antimalarial drugs in rheumatology. Interdisciplinary recommendations based on a systematic literature search].
Topics: Antimalarials; Antirheumatic Agents; Child; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemi | 2020 |
COVID-19 and what pediatric rheumatologists should know: a review from a highly affected country.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthritis, Juvenile; Beta | 2020 |
Should coronavirus disease 2019 concern rheumatologists?
Topics: Antirheumatic Agents; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans | 2020 |
Basic immunology may lead to translational therapeutic rationale: SARS-CoV-2 and rheumatic diseases.
Topics: Adaptive Immunity; Aged; Antirheumatic Agents; Comorbidity; Coronavirus Infections; COVID-19; COVID- | 2020 |
COVID-19, hydroxychloroquine and sudden cardiac death: implications for clinical practice in patients with rheumatic diseases.
Topics: Antirheumatic Agents; COVID-19; COVID-19 Drug Treatment; Death, Sudden, Cardiac; Humans; Hydroxychlo | 2021 |
Immunomodulatory therapies for SARS-CoV-2 infection: a systematic literature review to inform EULAR points to consider.
Topics: COVID-19; COVID-19 Drug Treatment; COVID-19 Serotherapy; Glucocorticoids; Humans; Hydroxychloroquine | 2021 |
Interventions for treating patients with chikungunya virus infection-related rheumatic and musculoskeletal disorders: A systematic review.
Topics: Antirheumatic Agents; Chikungunya Fever; Chikungunya virus; Chloroquine; Humans; Hydroxychloroquine; | 2017 |
Reappraisal of Antimalarials in Interferonopathies: New Perspectives for Old Drugs.
Topics: Antimalarials; Autoimmune Diseases; Humans; Hydroxychloroquine; Interferon Type I; Lupus Erythematos | 2018 |
Hydroxychloroquine: balancing the need to maintain therapeutic levels with ocular safety: an update.
Topics: Antirheumatic Agents; Chloroquine; Corneal Diseases; Dose-Response Relationship, Drug; Drug Administ | 2018 |
Hydroxychloroquine retinopathy - implications of research advances for rheumatology care.
Topics: Dose-Response Relationship, Drug; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Practic | 2018 |
Are the Current Recommendations for Chloroquine and Hydroxychloroquine Screening Appropriate?
Topics: Antimalarials; Chloroquine; Eye Diseases; Humans; Hydroxychloroquine; Patient Care Management; Rheum | 2019 |
[Rheumatic diseases in pregnancy].
Topics: Europe; Female; Humans; Hydroxychloroquine; Immunosuppressive Agents; Practice Guidelines as Topic; | 2013 |
Hydroxychloroquine-related retinal toxicity.
Topics: Antirheumatic Agents; Humans; Hydroxychloroquine; Optical Imaging; Retinal Diseases; Rheumatic Disea | 2016 |
The Pharmacological Mechanisms and Therapeutic Activities of Hydroxychloroquine in Rheumatic and Related Diseases.
Topics: Animals; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Rheumatoid; Humans; Hydroxychlor | 2017 |
Re-evaluation of antimalarials in treating rheumatic diseases: re-appreciation and insights into new mechanisms of action.
Topics: Annexin A5; Antimalarials; Antiphospholipid Syndrome; Antirheumatic Agents; Cardiovascular Diseases; | 2011 |
Ocular toxicity in children exposed in utero to antimalarial drugs: review of the literature.
Topics: Antimalarials; Child; Chloroquine; Databases, Factual; Eye; Eye Diseases; Female; Humans; Hydroxychl | 2011 |
Immunotherapies in rheumatologic disorders.
Topics: Abatacept; Adalimumab; Antibodies, Monoclonal; Antibodies, Monoclonal, Humanized; Antibodies, Monocl | 2012 |
[Gastrointestinal side effects in the therapy of rheumatologic diseases].
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Antibodies, Monoclonal; Antirheumatic | 2002 |
Anti-malarial drugs: possible mechanisms of action in autoimmune disease and prospects for drug development.
Topics: Antigen Presentation; Antimalarials; Autoantigens; Autoimmune Diseases; Chloroquine; Drug Design; Hi | 1996 |
Pharmacokinetics of hydroxychloroquine and chloroquine during treatment of rheumatic diseases.
Topics: Antirheumatic Agents; Biological Availability; Chloroquine; Drug Interactions; Humans; Hydroxychloro | 1996 |
Ophthalmological monitoring for hydroxychloroquine toxicity: a scientific review of available data.
Topics: Antirheumatic Agents; Corneal Diseases; Cost-Benefit Analysis; Dose-Response Relationship, Drug; Dru | 1997 |
Antimalarial drugs in the treatment of rheumatological diseases.
Topics: Antimalarials; Chloroquine; Contraindications; Female; Humans; Hydroxychloroquine; Male; Pregnancy; | 1997 |
Medical treatment of adolescents with rheumatic disease.
Topics: Adolescent; Adolescent Medicine; Adrenal Cortex Hormones; Anti-Inflammatory Agents, Non-Steroidal; A | 1998 |
[Problems of basic therapy of rheumatic diseases with chloroquine, gold and D-penicillamine].
Topics: Aurothioglucose; Chloroquine; Gold; Gold Sodium Thiomalate; Humans; Hydroxychloroquine; Penicillamin | 1979 |
Antimalarials in rheumatic diseases.
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Immunosuppressive Agents; Lysosomes; Rheumat | 1990 |
Management of rheumatoid arthritis.
Topics: Anti-Inflammatory Agents; Arthritis, Juvenile; Arthritis, Rheumatoid; Azathioprine; Chloroquine; Cyc | 1986 |
Antimalarials in rheumatology: efficacy and safety.
Topics: Antimalarials; Arthritis, Rheumatoid; Biomechanical Phenomena; Chloroquine; Clinical Trials as Topic | 1987 |
Ocular manifestations of rheumatic disorders. Natural and iatrogenic.
Topics: Adrenal Cortex Hormones; Arteritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Chloroquine; Conjunc | 1973 |
3 trials available for hydroxychloroquine and Rheumatic Diseases
| Article | Year |
|---|---|
Use of microperimetry to evaluate hydroxychloroquine and chloroquine retinal toxicity.
Topics: Adult; Antirheumatic Agents; Chloroquine; Cross-Sectional Studies; Electroretinography; Female; Fixa | 2013 |
A comparative study of the usefulness of color vision, photostress recovery time, and visual evoked potential tests in early detection of ocular toxicity from hydroxychloroquine.
Topics: Adult; Antirheumatic Agents; Color Vision; Early Diagnosis; Evoked Potentials, Visual; Eye Diseases; | 2011 |
Antimalarials in rheumatology: efficacy and safety.
Topics: Antimalarials; Arthritis, Rheumatoid; Biomechanical Phenomena; Chloroquine; Clinical Trials as Topic | 1987 |
91 other studies available for hydroxychloroquine and Rheumatic Diseases
| Article | Year |
|---|---|
Chronic use of hydroxychloroquine did not protect against COVID-19 in a large cohort of patients with rheumatic diseases in Brazil.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Arthritis, Rheumatoid; Brazil; Chi-Square Dist | 2021 |
Frequency and severity of COVID-19 in patients with various rheumatic diseases treated regularly with colchicine or hydroxychloroquine.
Topics: Colchicine; COVID-19 Drug Treatment; Humans; Hydroxychloroquine; Immunoglobulin G; Rheumatic Disease | 2022 |
Perspective of sarcoidosis in terms of rheumatology: a single-center rheumatology clinic experience.
Topics: Adrenal Cortex Hormones; Ambulatory Care Facilities; Anti-Inflammatory Agents, Non-Steroidal; Arthri | 2022 |
Development of SARS-CoV-2 infection in patients with rheumatic conditions on hydroxychloroquine monotherapy vs. patients without rheumatic conditions: A retrospective, propensity-matched cohort study.
Topics: Arthritis, Rheumatoid; Cohort Studies; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroquine | 2023 |
Immunogenicity of inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases.
Topics: Antibodies, Viral; Autoimmune Diseases; COVID-19; COVID-19 Vaccines; Humans; Hydroxychloroquine; Imm | 2022 |
Possible relationship between hydroxychloroquine and electrocardiographic and echocardiographic abnormalities in patients with inflammatory rheumatic diseases--a monocentric study.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; COVID-19; COVID-19 Drug Treatment; Cross-Sectional St | 2023 |
Cone Density Distribution and Related Factors in Patients Receiving Hydroxychloroquine Treatment.
Topics: Adolescent; Aged; Eye Injuries; Humans; Hydroxychloroquine; Retina; Retinal Cone Photoreceptor Cells | 2023 |
Effect of stopping hydroxychloroquine therapy on the multifocal electroretinogram in patients with rheumatic disorders.
Topics: Adult; Aged; Antirheumatic Agents; Electroretinography; Female; Fluorescein Angiography; Humans; Hyd | 2020 |
Factors determining response to Hydroxychloroquine therapy in palindromic rheumatism.
Topics: Arthritis, Rheumatoid; Humans; Hydroxychloroquine; Rheumatic Diseases | 2020 |
Use of Hydroxychloroquine and Chloroquine During the COVID-19 Pandemic: What Every Clinician Should Know.
Topics: Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Drug Reposi | 2020 |
What is the role of rheumatologists in the era of COVID-19?
Topics: Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antimalarials; Azetidines; Betacoronavir | 2020 |
Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?
Topics: COVID-19; Humans; Hydroxychloroquine; Rheumatic Diseases; Risk Factors; SARS-CoV-2 | 2021 |
Can hydroxychloroquine protect patients with rheumatic diseases from COVID-19? Response to: 'Does hydroxychloroquine prevent the transmission of COVID-19?' by Heldwein and Calado and 'SLE, hydroxychloroquine and no SLE patients with COVID-19: a comment' b
Topics: Antirheumatic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; Humans; Hydroxychloroquine; | 2020 |
How to manage rheumatic patients during the coronavirus pandemic.
Topics: Antirheumatic Agents; Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Di | 2020 |
American College of Rheumatology Guidance for the Management of Rheumatic Disease in Adult Patients During the COVID-19 Pandemic: Version 1.
Topics: Adult; Advisory Committees; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibito | 2020 |
Response to: 'Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?' by Erre
Topics: Antimalarials; Arrhythmias, Cardiac; COVID-19; Humans; Hydroxychloroquine; Inflammation; Rheumatic D | 2021 |
Antimalarial use and arrhythmias in COVID-19 and rheumatic patients: a matter of dose and inflammation?
Topics: Antimalarials; Antirheumatic Agents; Arrhythmias, Cardiac; COVID-19; Humans; Hydroxychloroquine; Inf | 2021 |
Comorbidities and rheumatological diseases at the time of COVID-19. Response to: 'Rheumatic diseases in intensive care unit patients with COVID-19' by Moiseev
Topics: COVID-19; Humans; Hydroxychloroquine; Intensive Care Units; Rheumatic Diseases; SARS-CoV-2 | 2021 |
Dr. Balevic,
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
Evidence of Protective Effect of Hydroxychloroquine on COVID-19.
Topics: Betacoronavirus; Coronavirus Infections; COVID-19; COVID-19 Drug Treatment; Humans; Hydroxychloroqui | 2020 |
Navigating COVID-19 in the developing world.
Topics: Antirheumatic Agents; Betacoronavirus; Chloroquine; Coronavirus Infections; COVID-19; Delivery of He | 2020 |
Response to: 'COVID-19 pandemic: an opportunity to assess the utility of telemedicine in patients with rheumatic diseases' by Lopez-Medina
Topics: COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Pandemics; Rheumatic Diseases; | 2021 |
Clinical features and outcomes of COVID-19 in patients with rheumatic diseases treated with biological and synthetic targeted therapies.
Topics: Adult; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Arthritis, | 2020 |
Still early to define a clear role of antimalarial drugs for COVID-19 in patients with rheumatic disease. Response to: 'Hydroxychloroquine reduces the risk of covid-19 in patients with rheumatic diseases: myth or reality?' by Xie
Topics: Antimalarials; COVID-19; Humans; Hydroxychloroquine; Rheumatic Diseases; SARS-CoV-2 | 2021 |
Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience.
Topics: Antirheumatic Agents; COVID-19; Humans; Hydroxychloroquine; Latin America; Pandemics; Rheumatic Dise | 2021 |
Clinical course, severity and mortality in a cohort of patients with COVID-19 with rheumatic diseases.
Topics: Adult; Aged; Antirheumatic Agents; Antiviral Agents; Arthritis, Psoriatic; Arthritis, Rheumatoid; Az | 2020 |
Effects of hydroxychloroquine treatment on QT interval.
Topics: Antirheumatic Agents; Atrial Fibrillation; Betacoronavirus; Coronavirus Infections; COVID-19; Drug M | 2020 |
COVID-19 and the practice of rheumatology in Africa: big changes to services from the shockwave of a pandemic.
Topics: COVID-19; Humans; Hydroxychloroquine; Pandemics; Rheumatic Diseases; Rheumatology; SARS-CoV-2 | 2021 |
Rheumatologists' practice during the Coronavirus disease 2019 (COVID-19) pandemic: a survey in Egypt.
Topics: Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Betacoronavirus; Cor | 2020 |
Determinants of COVID-19 disease severity in patients with underlying rheumatic disease.
Topics: Age Factors; Aged; Aged, 80 and over; Antibodies, Monoclonal, Humanized; Antirheumatic Agents; Antiv | 2020 |
Implications of SARS-CoV-2 infection for patients with rheumatic disease.
Topics: COVID-19; Humans; Hydroxychloroquine; Lupus Erythematosus, Systemic; Rheumatic Diseases; SARS-CoV-2 | 2022 |
Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study.
Topics: Adenosine Monophosphate; Age Factors; Aged; Alanine; Antiviral Agents; Arthritis, Psoriatic; Arthrit | 2020 |
Response to: 'Implications of SARS-CoV-2 infection for patients with rheumatic disease' by Lin
Topics: COVID-19; Humans; Hydroxychloroquine; Rheumatic Diseases; SARS-CoV-2 | 2022 |
COVID-19 and rheumatic musculoskeletal disease patients: infection rates, attitudes and medication adherence in an Irish population.
Topics: Adult; Antirheumatic Agents; Arthritis, Rheumatoid; Attitude to Health; Biological Products; Chloroq | 2021 |
Regulatory Action to Protect Access to Hydroxychloroquine for Approved Rheumatic Indications During COVID-19 in New Zealand.
Topics: Antirheumatic Agents; COVID-19 Drug Treatment; Drug and Narcotic Control; Evidence-Based Medicine; H | 2021 |
Chloroquine and hydroxychloroquine - safety profile of potential COVID-19 drugs from the rheumatologist's perspective.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; COVID-19 Drug Treatment; Eye; Female; Humans; Hydrox | 2021 |
Similar incidence of coronavirus disease 2019 (COVID-19) in patients with rheumatic diseases with and without hydroxychloroquine therapy.
Topics: Aged; COVID-19; Cross-Sectional Studies; Female; Humans; Hydroxychloroquine; Incidence; Male; Middle | 2021 |
Risk of coronavirus disease 2019 hospitalization and mortality in rheumatic patients treated with hydroxychloroquine or other conventional disease-modifying anti-rheumatic drugs in Italy.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Case-Control Studies; COVID-19; CO | 2021 |
Hydroxychloroquine Does Not Increase the Risk of Cardiac Arrhythmia in Common Rheumatic Diseases: A Nationwide Population-Based Cohort Study.
Topics: Antirheumatic Agents; Arrhythmias, Cardiac; Cohort Studies; Female; Humans; Hydroxychloroquine; Inci | 2021 |
Incidence and risk factors for moderate/severe COVID-19 in rheumatic diseases patients on hydroxychloroquine: a 24-week prospective cohort.
Topics: COVID-19; COVID-19 Drug Treatment; COVID-19 Testing; Humans; Hydroxychloroquine; Incidence; Prospect | 2022 |
Optical Coherence Tomography Protocols for Screening of Hydroxychloroquine Retinopathy in Asian Patients.
Topics: Adult; Aged; Antirheumatic Agents; Female; Follow-Up Studies; Fovea Centralis; Humans; Hydroxychloro | 2017 |
Optical Coherence Tomography Minimum Intensity as an Objective Measure for the Detection of Hydroxychloroquine Toxicity.
Topics: Adult; Aged; Antirheumatic Agents; Case-Control Studies; Electroretinography; Female; Humans; Hydrox | 2018 |
Early morpho-functional changes in patients treated with hydroxychloroquine: a prospective cohort study.
Topics: Antirheumatic Agents; Cohort Studies; Electroretinography; Female; Humans; Hydroxychloroquine; Male; | 2018 |
Pharmacokinetics of Hydroxychloroquine in Pregnancies with Rheumatic Diseases.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Models, Biological; Pregnancy; Rheu | 2019 |
Effect of in utero hydroxychloroquine exposure on the development of cutaneous neonatal lupus erythematosus.
Topics: Antirheumatic Agents; Autoimmune Diseases; Case-Control Studies; Female; Humans; Hydroxychloroquine; | 2018 |
The Validity of Optical Coherence Tomography Angiography as a Screening Test for the Early Detection of Retinal Changes in Patients with Hydroxychloroquine Therapy.
Topics: Adult; Aged; Antirheumatic Agents; Cross-Sectional Studies; Female; Fluorescein Angiography; Fovea C | 2019 |
Peripapillary Retinal Nerve Fiber Layer Thicknesses Did Not Change in Long-term Hydroxychloroquine Users.
Topics: Adult; Antirheumatic Agents; Female; Humans; Hydroxychloroquine; Male; Nerve Fibers; Optic Disk; Ret | 2018 |
Too Little of a Good Thing: Hydroxychloroquine in Pregnancy.
Topics: Female; Humans; Hydroxychloroquine; Infant, Newborn; Pregnancy; Pregnancy Complications; Rheumatic D | 2019 |
Early effect of hydroxychloroquine therapy: relationship between cumulative dose and retinal thickness.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Case-Control Studies; Dose-Response Relationship, Dru | 2015 |
Pericentral retinopathy and racial differences in hydroxychloroquine toxicity.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Asian People; Databases, Factual; Electroretin | 2015 |
Macular retinal ganglion cell-inner plexiform layer thickness in patients on hydroxychloroquine therapy.
Topics: Adult; Antirheumatic Agents; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Male; Nerve Fibe | 2014 |
Spectral-domain optical coherence tomography in hydroxychloroquine retinopathy.
Topics: Adult; Aged; Aged, 80 and over; Antirheumatic Agents; Humans; Hydroxychloroquine; Middle Aged; Retin | 2015 |
Pericentral hydroxychloroquine retinopathy in Korean patients.
Topics: Adult; Aged; Antirheumatic Agents; Asian People; Disease Progression; Female; Fluorescein Angiograph | 2015 |
New Perspectives in Rheumatology: Avoiding Antimalarial Toxicity.
Topics: Adult; Antimalarials; Biological Transport; Drug Monitoring; Drug-Related Side Effects and Adverse R | 2016 |
Frequency and Clinical Characteristics of Hydroxychloroquine Retinopathy in Korean Patients with Rheumatologic Diseases.
Topics: Adult; Aged; Antirheumatic Agents; Asian People; Drug Dosage Calculations; Female; Fluorescein Angio | 2017 |
Adherence to Hydroxychloroquine Dosing Guidelines by Rheumatologists: An Electronic Medical Record-Based Study in an Integrated Health Care System.
Topics: Antirheumatic Agents; Delivery of Health Care, Integrated; Dose-Response Relationship, Drug; Electro | 2017 |
Granuloma annulare.
Topics: Administration, Cutaneous; Adolescent; Adrenal Cortex Hormones; Adult; Anti-Infective Agents; Antirh | 2008 |
Retina in rheumatic diseases: standard full field and multifocal electroretinography in hydroxychloroquine retinal dysfunction.
Topics: Adult; Antirheumatic Agents; Electroretinography; Female; Humans; Hydroxychloroquine; Male; Middle A | 2011 |
Changes in glycosylated hemoglobin after initiation of hydroxychloroquine or methotrexate treatment in diabetes patients with rheumatic diseases.
Topics: Aged; Antirheumatic Agents; Arthritis, Rheumatoid; Blood Glucose; Diabetes Mellitus; Female; Glycate | 2010 |
Comparison of different screening methods for chloroquine/hydroxychloroquine retinopathy: multifocal electroretinography, color vision, perimetry, ophthalmoscopy, and fluorescein angiography.
Topics: Adult; Aged; Antirheumatic Agents; Chloroquine; Color Perception Tests; Diagnostic Techniques, Ophth | 2012 |
Use of hydroxychloroquine in Japan.
Topics: Antirheumatic Agents; Clinical Protocols; Clinical Trials as Topic; Health Services Accessibility; H | 2012 |
Palindromic rheumatism.
Topics: Adult; Drug Administration Schedule; Finger Joint; Humans; Hydroxychloroquine; India; Male; Pain Mea | 2002 |
Methotrexate is the leading DMARD in Finland.
Topics: Antirheumatic Agents; Arthritis, Rheumatoid; Finland; Humans; Hydroxychloroquine; Insurance, Health; | 2003 |
HAEMATOLOGICAL SIDE-EFFECTS OF SOME ANTI-RHEUMATIC DRUGS.
Topics: Aminopyrine; Antirheumatic Agents; Aspirin; Blood Platelets; Chloroquine; Colchicine; Complement Fix | 1963 |
[The treatment of inflammatory rheumatism by antimalarials (chloroquine and hydroxychloroquine)].
Topics: Antimalarials; Chloroquine; Humans; Hydroxychloroquine; Rheumatic Diseases; Rheumatic Fever | 1960 |
ERG findings in patients using hydroxychloroquine.
Topics: Adolescent; Adult; Aged; Antirheumatic Agents; Electroretinography; Female; Humans; Hydroxychloroqui | 2004 |
Follow-up of infants exposed to hydroxychloroquine given to mothers during pregnancy and lactation.
Topics: Antirheumatic Agents; Breast Feeding; Child Development; Female; Follow-Up Studies; Humans; Hydroxyc | 2005 |
Antimalarial myopathy: an underdiagnosed complication? Prospective longitudinal study of 119 patients.
Topics: Adult; Aged; Antimalarials; Antirheumatic Agents; Biopsy; Chloroquine; Clinical Enzyme Tests; Electr | 2006 |
Desensitization to hydroxychloroquine--experience of 4 patients.
Topics: Adult; Antirheumatic Agents; Desensitization, Immunologic; Drug Eruptions; Drug Hypersensitivity; Dr | 2006 |
Secondary myelodysplastic syndrome after hydroxychloroquine therapy.
Topics: Aged; Female; Humans; Hydroxychloroquine; Male; Myelodysplastic Syndromes; Retrospective Studies; Rh | 2007 |
Desensitization to hydroxychloroquine: alternative interpretations.
Topics: Antirheumatic Agents; Desensitization, Immunologic; Drug Eruptions; Drug Hypersensitivity; Drug Tole | 2007 |
The use of drugs in rheumatic diseases.
Topics: Analgesics; Anti-Inflammatory Agents; Aspirin; Aurothioglucose; Chloroquine; Colchicine; Gold Sodium | 1984 |
Pharmacologic actions of 4-aminoquinoline compounds.
Topics: Aminoquinolines; Cell Membrane; Chloroquine; Exocytosis; Half-Life; Hemin; Humans; Hydroxychloroquin | 1983 |
What drugs for rheumatic diseases?
Topics: Adrenal Cortex Hormones; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Go | 1981 |
Hydroxychloroquine and pain thresholds.
Topics: Adult; Female; Humans; Hydroxychloroquine; Pain Threshold; Rheumatic Diseases | 1995 |
Possible mechanisms of action of antimalarials in rheumatic disease.
Topics: Cells; Chloroquine; Humans; Hydroxychloroquine; Kinetics; Rheumatic Diseases | 1993 |
Therapy for childhood rheumatic diseases. Have we been doing enough?
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Child; Child, Pr | 1993 |
Hydroxychloroquine therapy in rheumatic diseases.
Topics: Humans; Hydroxychloroquine; Rheumatic Diseases | 1995 |
Hypergammaglobulinemic purpura in systemic autoimmune rheumatic diseases: predictive value of anti-Ro(SSA) and anti-La(SSB) antibodies and treatment with indomethacin and hydroxychloroquine.
Topics: Adult; Aged; Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents | 1995 |
Fibroblastic rheumatism: a fifteen-year followup study.
Topics: Adult; Anti-Inflammatory Agents, Non-Steroidal; Antirheumatic Agents; Arthrography; Fibroblasts; Fol | 1998 |
Antimalarial drugs in the treatment of rheumatological diseases.
Topics: Aged; Antimalarials; Antirheumatic Agents; Humans; Hydroxychloroquine; Retina; Retinal Diseases; Rhe | 1998 |
Long-term effectiveness of antimalarial drugs in rheumatic diseases.
Topics: Adult; Antimalarials; Antirheumatic Agents; Arthritis; Arthritis, Rheumatoid; Chloroquine; Female; F | 1998 |
Ocular toxicity and antenatal exposure to chloroquine or hydroxychloroquine for rheumatic diseases.
Topics: Antirheumatic Agents; Child; Child, Preschool; Chloroquine; Female; Humans; Hydroxychloroquine; Infa | 2001 |
Antirheumatic agents.
Topics: Adrenal Cortex Hormones; Antimalarials; Aspirin; Azathioprine; Chloroquine; Cyclophosphamide; Gold; | 1979 |
Bone and joint diseases in the elderly.
Topics: Activities of Daily Living; Adrenal Cortex Hormones; Age Factors; Aged; Anti-Inflammatory Agents; Ar | 1976 |
Drug therapy in the rheumatic diseases.
Topics: Anti-Inflammatory Agents; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Rheumatoid; Gold; Huma | 1992 |
Therapeutic significance of laboratory results in rheumatic disease.
Topics: Anti-Inflammatory Agents; Arthritis, Reactive; Aspirin; Blood Viscosity; C-Reactive Protein; Captopr | 1985 |
Office management of rheumatic disease. Pharmacology and laboratory evaluation.
Topics: Ambulatory Care; Anti-Inflammatory Agents, Non-Steroidal; Clinical Laboratory Techniques; Cyclophosp | 1988 |
Estimation of plasma hydroxychloroquine by high-performance liquid chromatography with ultraviolet detection.
Topics: Biotransformation; Chromatography, High Pressure Liquid; Humans; Hydroxychloroquine; Rheumatic Disea | 1985 |
[Electrometric demonstration of hypersensitivity to antirheumatic drugs].
Topics: Anti-Inflammatory Agents; Antimalarials; Drug Eruptions; Gold; Humans; Hydroxychloroquine; Methods; | 1970 |
The management of keratoconjuctivitis sicca.
Topics: Anesthetics; Autoimmune Diseases; Bicarbonates; Chloramphenicol; Cysteine; Dextrans; Heparin; Herpes | 1965 |